Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

Learn more about:
Related Clinical Trial
Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma Adjuvant Melatonin for Uveal Melanoma Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma Managed Access Program Supporting Patient Access to Tebentafusp Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Early Integration of Supportive Care Into Standard Oncology Care for Metastatic Uveal Melanoma Patients Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma A Prospective Natural History Study in Uveal Melanoma Uveal Melanoma and Brachytheraphy: Long-term Outcomes. A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation and Randomized, Masked Dose Expansion Designed to Evaluate Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery A Study of PLX2853 in Advanced Malignancies. Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) Treatment Of Radiation Retinopathy Trial Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Study in Subjects With Small Primary Choroidal Melanoma Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Trial of AEB071 in Combination With BYL719 in Patients With Melanoma Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Pembrolizumab in Treating Patients With Advanced Uveal Melanoma Vascular Response to Brachytherapy Using Functional OCT Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma New Biopsy Technique for Uveal Melanoma Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy Intermittent Selumetinib for Uveal Melanoma Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0) Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma Vorinostat in Patients With Class 2 High Risk Uveal Melanoma Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases A Phase II Study of BVD-523 in Metastatic Uveal Melanoma Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma Treatment With Intravitreal Avastin for Large Uveal Melanomas

Brief Title

Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

Official Title

Phase II Randomized Trial of Stereotactic Radiotherapy (SRT) Followed by Intravitreal Aflibercept Injection for Patients With Ocular Melanoma

Brief Summary

      This phase II trial studies how well stereotactic body radiation therapy and aflibercept work
      in treating patients with uveal melanoma. Stereotactic body radiation therapy is a
      specialized radiation therapy that sends x-rays directly to the tumor using smaller doses
      over several days and may cause less damage to normal tissue. Aflibercept may stop the growth
      of tumor cells by blocking some of the enzymes needed for cell growth. Giving stereotactic
      body radiation therapy followed by aflibercept may work better in treating patients with
      uveal melanoma.

Detailed Description


      I. To assess the percentage of patients able to successfully complete their prescribed
      treatment of radiation and intravitreal ziv-aflibercept (aflibercept) injection (IAI) with an
      acceptable level of toxicity.


      I. To assess for reduction in the incidence of 2-year rates of radiation maculopathy,
      radiation papillopathy, functional vision preservation, radiation glaucoma, and to assess
      2-year local control and progression-free survival.

Study Phase

Phase 2

Study Type


Primary Outcome

Incidence of grade 3 or higher toxicity according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

Secondary Outcome

 Radiation maculopathy rate defined as ophthalmoscopic detection of macular edema perivascular sheathing


Uveal Melanoma


Stereotactic Body Radiation Therapy

Study Arms / Comparison Groups

 A. Stereotactic body radiation therapy, ziv-aflibercept
Description:  Patients undergo stereotactic body radiation therapy over 5 fractions every other week day during days 1-10. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

August 9, 2019

Completion Date

July 2024

Primary Completion Date

October 9, 2023

Eligibility Criteria

        Inclusion Criteria:

          -  Provide signed and dated informed consent form or have a Legally Authorized
             Representative (LAR) who can give consent

          -  Willing to comply with all study procedures and be available for the duration of the

          -  Must be a candidate for radiation therapy

          -  Karnofsky performance status (KPS) >= 60

          -  Diagnosed with uveal melanoma either clinically or pathologically on biopsy

          -  Uveal melanoma of one eye only

          -  Localized uveal melanoma, with no evidence of metastasis

          -  Women of childbearing potential must have a negative urine or serum pregnancy test
             within 14 days prior to enrollment

        Exclusion Criteria:

          -  Tumor thickness more than 14 mm as measured by ultrasound

          -  Active collagen vascular disease

          -  Any contraindication to intravitreal injections including: elevated intraocular
             pressure, ocular or periocular infection, active intraocular inflammation, or other
             determined by treating physician

          -  Known allergic reactions to components of intravitreal Aflibercept

          -  Patients with known hypercoagulable syndromes

          -  Prior radiation to the eye or brain

          -  Life expectancy less than 6 months

          -  Blind in both eyes

          -  Patients unable to receive contrast enhanced brain magnetic resonance imaging (MRI)

          -  Deaf in both ears

          -  Patients have hypersensitivity to intravitreal Aflibercept

          -  Patients is on or within 1 month of systemic anti-VEGF treatment

          -  Patients who are candidates for brachytherapy

          -  Patients for whom enucleation is standard of care

          -  Pregnancy or active breastfeeding. Sexually active men or women of childbearing
             potential who are unwilling to practice adequate contraception prior to the initial
             dose/start of the first treatment, during the study, and for at least 3 months after
             the last dose. Adequate contraceptive measures include stable use of oral
             contraceptives or other prescription pharmaceutical contraceptives for 2 or more
             menstrual cycles prior to screening; intrauterine device; bilateral tubal ligation;
             vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus
             contraceptive sponge, foam, or jelly

               -  Contraception is not required for men with documented vasectomy

               -  Postmenopausal women must be amenorrheic for at least 12 months in order not to
                  be considered of childbearing potential. Pregnancy testing and contraception are
                  not required for women with documented hysterectomy or tubal ligation




18 Years - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers


Wenyin Shi, MD, PhD, (215) 955-6702, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Sidney Kimmel Cancer Center at Thomas Jefferson University


 Regeneron Pharmaceuticals

Study Sponsor

Wenyin Shi, MD, PhD, Principal Investigator, Sidney Kimmel Cancer Center at Thomas Jefferson University

Verification Date

September 2022